Skip to content
Bored Studies
RecruitingPhase 3

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Alexion Pharmaceuticals, Inc. · NCT06830798

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
450
US sites recruiting
30
Study start
May 19, 2025
Record last updated
June 18, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Being studied: Ravulizumab; Placebo

Conditions: Delayed Graft Function; DGF; Kidney Transplant

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • ≥ 18 years of age at the time of signing the informed consent
  • Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)
  • A candidate for kidney transplant from:
  • Donation after Circulatory Death (DCD) donor
  • High-risk Donation after Brain Death (DBD) donor

Exclusion Criteria

  • Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification
  • Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.

Recruiting US locations

Study contacts (from the official record)

  • Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Double-blind, Randomized, Placebo-controlled, Multicenter Study to… (NCT06830798) | Bored Studies